Cancer Chemotherapy and Pharmacology

, Volume 27, Issue 6, pp 477–480 | Cite as

Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer

  • Hellmut Samonigg
  • Herbert Stöger
  • Anne-Katrin Kasparek
  • Marianne Schmid
  • Johann Dusleag
  • Karl Pfeiffer
  • Michael Smola
  • Peter Steindorfer
  • Peter Lechner
Original Articles Prednimustine, Mitoxantrone, 5-Fluorouracil, Chemotherapy, Advanced Breast Cancer

Summary

A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1–5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF). Treatment was repeated every 3 weeks. In all 53 patients were evaluable for response. A total of 12 subjects had failed prior chemotherapy for metastatic disease. In response to PMF treatment we observed 21 partial remissions and 3 complete remissions, amounting to a total response rate of 45%. The median duration of response was 39 weeks, and median survival was 56 weeks. Doselimiting side effects were leukopenia (40 cases) and thrombocytopenia (11 patients). Nausea and vomiting was experienced by 93% of subjects; in 56% of cases it reached WHO stage II–III. Alopecia occured in 18% of our patients. Our results suggest that PMF represents an active regimen in the treatment of advanced breast cancer and yields a response rate of 45%. Considering that the majority of our patients had not received prior chemotherapy, the question remains open as to whether a 45% response rate outweighs the observed toxicity.

Keywords

Breast Cancer Cancer Research Median Survival Thrombocytopenia Metastatic Disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Allegra JC, Woodcock T, Woolf S, Henderson IC, Bryan S, Reisman A (1985) A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer. Invest New Drugs 3: 153–161Google Scholar
  2. 2.
    Andersson M, Philip P, Pedersen-Bjergaard J (1990) High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil. mitoxatrone and tamoxifen for advanced breast cancer. Cancer 65: 2460–2464Google Scholar
  3. 3.
    Bennet JM, Byrne P, Desai A (1985) A randomized multicenter trial of cyclophosphamide, novantrone and 5-FU (CNF) versus CAF in patients with metastatic breast cancer. Invest New Durgs 3: 179–185Google Scholar
  4. 4.
    Blumenschein GR, Hortobagyi GN, Richman SP, Tutterman JU, Takashima CK, Buzdar AU, Burgess MA, Livington RB, Hersh EM (1980) Altemating non-cross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma. Cancer 45: 742–749Google Scholar
  5. 5.
    Cowan JD, Osborne CK, Neidhart JA, von Hoff DD, Constanzi JJ, Vaughn CB (1985) A randomized trial of doxorubicin, mitroxantrone and bisantrene in advanced breast cancer (a Southwest Oncology Group study). Invest New Drugs 3: 149–152Google Scholar
  6. 6.
    Follezou JY, Palangle T, Feullhade F (1987) Essai randomise comparant la mitoxantrone a l'adriamycine dans les cancers du sein evolues. Presse Med 16: 765–768Google Scholar
  7. 7.
    Holmes FA, Yap HY, Esparza L, Buzdar AU, Blumenschein GR, Hug V, Hortobagyi GN (1987) Mitoxantrone, cyclophosphamide and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. Cancer 59:1992–1999Google Scholar
  8. 8.
    Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Buzdar AU, Burgess MA, Livington RB, Valdivieso M, Gutterman JU, Hersh EM, Bodey GP (1979) Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil. Adriamycin, cyclophosphamide, and BCG. Cancer 43:1225–1233Google Scholar
  9. 9.
    Hortobagyi GN, Blumenschein GR, Tashima CK, Buzdar AU, Burgess MA, Livington RB, Valdivieso M, Gutterman JU, Hersh EM, Bodey GP (1979) Ftorafur, Adriamycin, Cyclophosphamide, and BCG in the treatment of metastatic breast cancer. Cancer 44: 398–405Google Scholar
  10. 10.
    Könyves I, Nordenskjöld B, Plym-Forshell G, De Schryver A, Westerberg-Larsson H (1975) Preliminary clinical and absorption studies with prednimustine in patients with mammary carcinoma. Eur J Cancer 11:841–844Google Scholar
  11. 11.
    Lenk H, Müller U, Tauneberger S (1987) Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res 7: 1257–1264Google Scholar
  12. 12.
    Löber J (1983) A phase III trial comparing prednimustine (Leo 1031) to chlorambucil plus prednisolone in advanced breast cancer. Cancer 52:1570–1576Google Scholar
  13. 13.
    Martoni A, Rani P, Ercolino L, Canova N, Pannuti F (1988) Mitroxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. Chemioterapia 7:345–349Google Scholar
  14. 14.
    Mouridsen HT (1986) Prednimustine in advanced breast cancer: a review. Sem Oncol 13 (1) [Suppl 1]:27–31Google Scholar
  15. 15.
    Mouridsen HT, Kristensen D, Halskov-Nielsen J, Dombernowsky P (1980) Phase II trial of prednimustine, L-1031 (NSC-134087), in advanced breast cancer. Cancer 46:253–255Google Scholar
  16. 16.
    Nemoto T, Horton J, Simon R, (1982) Comparison of four combination chemotherapy programs in metastatic breast cancer. Cancer 49: 1988–1993Google Scholar
  17. 17.
    Saletan S (1987) Mitoxantrone: an active, new antitumor agent with an improved theapeutic index. Cancer Treat Rev 14:297–303Google Scholar
  18. 18.
    Savaraj N, Lu K, Valdivieso M, Loo TL (1982) Pharmacology of mitoxantrone in cancer patients. Cancer Chemother Pharmacol 8: 113–117Google Scholar
  19. 19.
    Smalley RV, Carpenter J, Bartolucci A, Vogel C, Krauss S (1977) A comparison of cyclophosphamide, Adriamycin, 5-fluoruracil (CAF). Cancer 40:625–632Google Scholar
  20. 20.
    Stuart-Harris RC, Bozek T, Pavidis NA, Smith IE (1984) Mitoxantrone: an active new agent in the treatment of advanced breast cancer. Cancer Chemother Pharmacol 12:1–4Google Scholar
  21. 21.
    Tormey DC, Gelman R, Band PR, Sears M, Rosenthal SN, Dewys W, Perlia C, Rice MA (1982) Comparison of induction chemotherapies for metastatic breast cancer. Cancer 50:1235–1244Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • Hellmut Samonigg
    • 1
  • Herbert Stöger
    • 1
  • Anne-Katrin Kasparek
    • 1
  • Marianne Schmid
    • 1
  • Johann Dusleag
    • 1
  • Karl Pfeiffer
    • 2
  • Michael Smola
    • 3
  • Peter Steindorfer
    • 3
  • Peter Lechner
    • 4
  1. 1.Department of Internal MedicineKarl Franzens-University at GrazGrazAustria
  2. 2.Department of PhysiologyKarl Franzens-University at GrazGrazAustria
  3. 3.Department of SurgeryKarl Franzens-University at GrazGrazAustria
  4. 4.Second Department of SurgeryLandeskrankenhaus GrazGrazAustria

Personalised recommendations